Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eaton Vance Ohio Municipal Income Trust (NQ: EVO )

4.490 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eaton Vance Ohio Municipal Income Trust

< Previous 1 2 3 4 5 6 7 8 Next >
Evotec Adds Cell Therapy Manufacturing Facility with Acquisition of Rigenerand
CELLS PLATFORM INTEGRATES INNOVATIVE OFF-THE-SHELF IPSC CELL THERAPY DISCOVERY WITH DEVELOPMENT AND MANUFACTURING 
From Evotec AE
Via AccessWire
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Evotec and Almirall Enter into a Multi-Target Alliance in Medical Dermatology
HAMBURG, GERMANY and BARCELONA, SPAIN / ACCESSWIRE / May 19, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) and Almirall S.A. (ALM), a global... 
From Evotec AG
Via AccessWire
Sernova, Evotec Join Forces To Develop 'Functional Cure' For Diabetes
Via Benzinga
Earnings Scheduled For May 11, 2022
Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter. 
Via Benzinga
TYME Technologies Reviews Potential Strategic Options
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
52 Stocks Moving In Wednesday's Mid-Day Session
Gainers Trecora Resources (NYSE: TREC) shares jumped 26.6% to $9.56 as the company agreed to be acquired by an affiliate of Balmoral Funds at $9.81 per share in cash or an enterprise value of $247... 
Via Benzinga
99 Biggest Movers From Yesterday
Gainers Armstrong Flooring, Inc. (NYSE: AFI) shares jumped 237% to settle at $0.49 on Wednesday after a 13D filing showed Esopus Creek Advisors LLC disclosed a 5.1% active stake in the company. 
Via Benzinga
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning and welcome back for another busy day of trading as we cover the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
34 Stocks Moving in Wednesday's Pre-Market Session
Gainers Embark Technology, Inc. (NASDAQ: EMBK) rose 36.4% to $1.95 in pre-market trading. Embark Technology posted a Q1 loss of $0.04 per share. 
Via Benzinga
Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership
HAMBURG, GERMANY / ACCESSWIRE / May 10, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces today that the Company has extended and... 
From Evotec AG
Via AccessWire
Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership in Protein Degradation
- 8-YEAR EXTENSION AND EXPANSION OF COLLABORATION TO DEVELOP PIPELINE OF MOLECULAR GLUE DEGRADERS - COLLABORATION LEVERAGES EVOTEC'S PROPRIETARY EVO PANOMICS AND EVO PANHUNTER PLATFORMS COVERING... 
From Evotec AG
Via AccessWire
Evotec SE to Announce Results for the First Quarter 2022 on 11 May 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From Evotec AG
Via AccessWire
Pasithea Biotech Reports That It's Aiming To Be At The Forefront Of The Mental Health Revolution
Image provided by Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
24 Biggest Movers From Yesterday
Gainers Vertical Aerospace Ltd. (NYSE: EVTL) Shares hiked 30.93% to close at $9.82 on Tuesday after Deutsche Bank initiated coverage of the stock. Peabody Energy Corporation (... 
Via Benzinga
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Evotec SE Fiscal Year 2021 Results: 'Setting the Pace' on the Data-Driven R&D Autobahn to Cures
- STRONG FINANCIAL RESULTS: 23% INCREASE IN GROUP REVENUES SIGNIFICANTLY EXCEEDING GUIDANCE - DATA-DRIVEN PLATFORMS AND TECHNOLOGIES INCREASE PROBABILITIES OF SUCCESS IN ALL MODALITIES - SUBSTANTIALLY... 
From Evotec AG
Via AccessWire
Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb
- THE PROGRAMME DESIGNATION IS BASED ON AN ANTISENSE-BASED APPROACH WHICH TRIGGERS A US$ 16 M PAYMENT TO EVOTEC BY BRISTOL MYERS SQUIBB - EVOTEC SOURCES LNAPLUS(TM) ANTISENSE TECHNOLOGY THROUGH A... 
From Evotec AG
Via AccessWire
Evotec SE to Announce Results for Fiscal Year 2021 on 12 April 2022
HAMBURG, GERMANY / ACCESSWIRE / April 5, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809); (NASDAQ:EVO) will announce its financial results for 2021 on Tuesday, 12 April... 
From Evotec AG
Via AccessWire
Evotec Receives € 3 m Milestone Payment for Bayer Starting Phase II Clinical Development of DNP Programme
- FIRST DOSING OF A STUDY PARTICIPANT TRIGGERS MILESTONE PAYMENT OF € 3 M TO EVOTEC - PHASE II CLINICAL TRIAL INITIATED BY EVOTEC'S PARTNER BAYER TO EVALUATE BAY 2395840 AS A POTENTIAL TREATMENT FOR... 
From Evotec AG
Via AccessWire
Evotec Presents Strategic Roadmap Towards Precision Medicine and Confirms Goals of Action Plan 2025 at Capital Markets Day
- LAUNCH OF E.MPD, THE LEADING GLOBAL MOLECULAR PATIENT DATABASE - ROLL-OUT AND ACCELERATION OF AI/ML PRECISION TECHNOLOGIES TO INCREASE PROBABILITY OF SUCCESS ("POS") IN RESEARCH, DEVELOPMENT, AND... 
From Evotec AG
Via AccessWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Evotec Expands Molecular Patient Database with Unique Nephrotic Syndrome Cohort from the University of Bristol
- EVOTEC RECEIVES ACCESS TO AN INTERNATIONAL COHORT OF NEPHROTIC SYNDROME PATIENTS COORDINATED BY THE UNIVERSITY OF BRISTOL - THE COHORT PROVIDES LONGITUDINAL ACCESS NOT ONLY TO CLINICAL DATA BUT IN... 
From Evotec AG
Via AccessWire
Stocks That Hit 52-Week Lows On Monday
On Monday, 71 stocks hit new 52-week lows. Noteable 52-Week Lows: 3M (NYSE:MMM) was the biggest company in terms of market cap to set a new 52-week low. OceanPal (... 
Via Benzinga
50 Biggest Movers From Friday
Also check out this: Executives Sell Over $45M Of 5 Stocks Losers Ra Medical Systems, Inc. (NYSE: RMED) shares dipped 48.8% to close at $0.3599 on Friday after the... 
Via Benzinga
Why Are Evotec Shares Trading Lower On Friday?
Bayer AG (OTC: BAYRY) has  
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers iRadimed (NASDAQ:IRMD) stock rose 15.0% to $45.19 during Friday's regular session. Trading volume for iRadimed's stock is 94.1K as of 12:30 EST. This is... 
Via Benzinga
Bayer Discontinues Clinical Development Candidate Eliapixant (BAY1817080), Evotec Regains the Rights to all P2X3 Assets
HAMBURG, GERMANY / ACCESSWIRE / February 4, 2022 / Evotec SE (Frankfurt Stock Exchange, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ) announces today that the Company has been informed by... 
From Evotec AG
Via AccessWire
The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Pfizer, BioNTech Initiates Study Of Omicron-Based Vaccine Candidate Pfizer,... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.